Skip to contentP
Processa Pharmaceuticals, Inc.
P
PCSAProcessa Pharmaceuticals, Inc. Q3 2019 · 10-Q
Revenue—
Net Income-$863.52K-$863.52KN/M vs Q3 2018 EPS Diluted-$0.16-$0.16N/M vs Q3 2018 Operating Income-$1,004,007N/M Operating Cash Flowderived-$217,683N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
ended Sep 30, 2019 · filed Nov 14, 2019 · 45 d after period end